#44 Dr Jack Hoppin and Dr John Babich - Precision-based cancer targeting with Ratio Therapeutics

What: Ratio is an early clinical-phase pharmaceutical company whose mission is to accelerate the development of best-in-class radiopharmaceuticals for cancer patients. The company has raised over USD $40 million to date in funding and developed two novel proprietary platforms: Trillium™ and Macropa™.  Who: Jack is CEO of Ratio and a mathematician by training, with John as CSO and a former professor of Radiopharmaceutical Sciences at Cornell University. They began working together in 2018 and the company is named after the mathematical approach to radiopharmaceuticals development.  We talk about: Evolving and scaling what was a small-stage pharma company to a multi-million dollar player, and the pros and cons of co-founding a business with your friends. 📝 You can also now read the accompanying "podnotes" to the episode on Substack, where key insights from every conversation will be shared for those who prefer short and snappy takeaways: founderskeepers.substack.com  Find out more:  www.founders-keepers.com  Instagram: @founderskeepers.pod  Twitter: @founders.pod  LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast  Get in touch: hi@founders-keepers.com